Stati Uniti - inglese - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - phenelzine sulfate (unii: 2681d7p965) (phenelzine - unii:o408n561gf) - phenelzine 15 mg - phenelzine sulfate tablets, usp has been found to be effective in depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic." these patients often have mixed anxiety and depression and phobic or hypochondriacal features. there is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. phenelzine sulfate tablets should rarely be the first antidepressant drug used. rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. phenelzine sulfate tablets should not be used in patients who are hypersensitive to the drug or its ingredients, with pheochromocytoma, congestive heart failure, severe renal impairment or renal disease, a history of liver disease, or abnormal liver function tests. the potentiation of sympathomimetic substances and related compounds by mao inhibitors may result in hypertensive crises (see warnings). therefore, patients being treated with phenelzi

Stati Uniti - inglese - NLM (National Library of Medicine)

greenstone llc - phenelzine sulfate (unii: 2681d7p965) (phenelzine - unii:o408n561gf) - phenelzine 15 mg - phenelzine sulfate has been found to be effective in depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic." these patients often have mixed anxiety and depression and phobic or hypochondriacal features. there is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. phenelzine sulfate should rarely be the first antidepressant drug used. rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. phenelzine sulfate should not be used in patients who are hypersensitive to the drug or its ingredients, with pheochromocytoma, congestive heart failure, severe renal impairment or renal disease, a history of liver disease, or abnormal liver function tests. the potentiation of sympathomimetic substances and related compounds by mao inhibitors may result in hypertensive crises (see warnings). therefore, patients being treated with phenelzine sulfate should not take sy

Stati Uniti - inglese - NLM (National Library of Medicine)

novel laboratories, inc. - phenelzine sulfate (unii: 2681d7p965) (phenelzine - unii:o408n561gf) - phenelzine 15 mg - phenelzine sulfate tablets, usp has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” these patients often have mixed anxiety and depression and phobic or hypochondriacal features. there is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. phenelzine sulfate tablets should rarely be the first antidepressant drug used. rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. phenelzine sulfate tablets should not be used in patients who are hypersensitive to the drug or its ingredients, with pheochromocytoma, congestive heart failure, severe renal impairment or renal disease, a history of liver disease, or abnormal liver function tests. the potentiation of sympathomimetic substances and related compounds by mao inhibitors may result in hypertensive crises (see warnings). therefore, patients being treated with phenelzi

Stati Uniti - inglese - NLM (National Library of Medicine)

parke-davis div of pfizer inc - phenelzine sulfate (unii: 2681d7p965) (phenelzine - unii:o408n561gf) - phenelzine 15 mg - nardil has been found to be effective in depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic." these patients often have mixed anxiety and depression and phobic or hypochondriacal features. there is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. nardil should rarely be the first antidepressant drug used. rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. nardil should not be used in patients who are hypersensitive to the drug or its ingredients, with pheochromocytoma, congestive heart failure, severe renal impairment or renal disease, a history of liver disease, or abnormal liver function tests. the potentiation of sympathomimetic substances and related compounds by mao inhibitors may result in hypertensive crises (see warnings). therefore, patients being treated with nardil should not take sympathomimetic drugs (including amphetamines, co

Stati Uniti - inglese - NLM (National Library of Medicine)

golden state medical supply, inc. - phenelzine sulfate (unii: 2681d7p965) (phenelzine - unii:o408n561gf) - phenelzine 15 mg

Stati Uniti - inglese - NLM (National Library of Medicine)

american health packaging - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 15 mg - dextroamphetamine sulfate extended-release capsules are indicated in: narcolepsy attention deficit disorder with hyperactivity – as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poo

Stati Uniti - inglese - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use morphine sulfate extended-release tablets are contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal withdrawal syndrome [see warnings and precautions (5.3)] . there are no available data with morphine sulfate extended-release tablets in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published studies with morphine use during pregnancy have not reported a clear association with morphine and major birth defects [see human data]. in published animal reproduction studies, morphine administered subcutaneously during the early gestational period produced neural tube defects (i.e., exencephaly and cranioschisis) at 5 and 16 times the human daily dose of 60 mg based on body surf

Stati Uniti - inglese - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg - dextroamphetamine sulfate extended-release capsules are indicated in: narcolepsy as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained ment

Stati Uniti - inglese - NLM (National Library of Medicine)

lineage therapeutics inc - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg - dextroamphetamine sulfate is indicated in: as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoid tasks requiring sustained mental effort; loses things; easily distracted;

Stati Uniti - inglese - NLM (National Library of Medicine)

par pharmaceutical - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. morphine sulfate extended-release tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial